• About us
• Contact

Advertisement

Organisation › Details

Insilico Medicine Hong Kong Ltd.

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in six countries sourced through hackathons and competitions. The company and its scientists are dedicated to transforming the pharmaceutical industry by developing and applying the next-generation deep learning approaches to every step of the drug discovery and drug development process. The company is constantly collaborating with the most innovative biopharmaceutical companies with disease-relevant assays to validate its solutions and generate high-quality machine-learnable data. Since 2015 Insilico Medicine is developing a broad range of generative adversarial networks (GANs) and reinforcement learning approaches to identify novel protein targets, generate novel molecular structures with specified properties and generate synthetic data. *

 

	Start	2019-08-19 existent
	Group	Insilico Medicine (Group)
	Industry	artificial intelligence (AI) / machine learning (ML)
	Industry 2	AI-based drug discovery software
	Person	Zhavoronkov, Alex (Insilico Medicine 202007 CEO + Founder)
	Person 2	Ren, Feng (Insilico Medicine 202211 Co-CEO + CSO)
	Region	Hong Kong
	Country	China
	Street	5 Science Park West Avenue Rm 8, Unit 111-113, ICT Co-Working Centre 1/F, Enterprise Place
	City	Hong Kong
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«: Insilico Medicine. (9/10/19). "Press Release: Insilico Medicine Secures $37m in Series B Funding Led by Qiming Venture Partners". Hong Kong.
		Record changed: 2024-01-21

Advertisement

More documents for Insilico Medicine (Group)

• [1] Menarini Group. (1/4/24). "Press Release: Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications". Florence & New York, NY....
• [2] Insilico Medicine. (11/8/22). "Press Release: Insilico Medicine Signs Strategic Research Collaboration with Sanofi Worth up to $1.2 Billion". New York, NY....
• [3] Centogene N.V.. (1/20/22). "Press Release: Centogene Joins Forces with Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development". Cambridge, MA, Rostock & Berlin...
• [4] Insilico Medicine Hong Kong Ltd.. (6/22/21). "Press Release: Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus". New York, NY & Hong Kong....
• [5] Insilico Medicine. (4/27/20). "Press Release: Insilico Medicine Enters into a Collaboration Research with Astellas Pharma Inc. to Apply Novel Generative Artificial Intelligence System for a Conventionally Challenging Target Family". Tsukuba....
• [6] Insilico Medicine. (4/14/20). "Press Release: Insilico Enters into a Research Collaboration with Boehringer Ingelheim to Apply Novel Generative Artificial Intelligence System for Discovery of Potential Therapeutic Targets". Hong Kong....
• [7] Insilico Medicine. (3/16/20). "Press Release: Beijing Tide Pharmaceutical and Insilico Medicine Enter into a Strategic Partnership Agreement for Cancer Therapy". Beijing & Hong Kong....
• [8] Insilico Medicine. (10/9/19). "Press Release: CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Worth Up to $200 million". Hong Kong & Nanjing....
• [9] Insilico Medicine. (9/10/19). "Press Release: Insilico Medicine Secures $37m in Series B Funding Led by Qiming Venture Partners". Hong Kong....
• [10] Insilico Medicine. (6/11/18). "Press Release: WuXi AppTec Leads Strategic Investment in Insilico Medicine to Accelerate Drug Discovery Using Next-Generation Artificial Intelligence". Baltimore, MD & Shanghai....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.